ANO1 and hepatocellular carcinoma: In line with our results, decreased migration and invasion activity with inhibition of ANO1 have been reported in gastric carcinoma [9], hepatocellular carcinoma [10], lung cancer [15], oral squamous cell carcinoma [13], prostatic carcinoma [32], colorectal carcinoma [17], and glioma [12].